Tag Archives: Michael Higgins

Cerecor Inc (CERC) Gets a Buy Rating from Ladenburg

In a report released today, Michael Higgins from Ladenburg reiterated a Buy rating on Cerecor Inc (CERC – Research Report), with a price target of $8. The company’s shares closed on Friday at $5.02. Higgins commented: “We expect CERC-800s’ development

Ladenburg Believes Palatin Technologies (NYSE MKT: PTN) Won’t Stop Here

In a report issued on May 10, Michael Higgins from Ladenburg maintained a Buy rating on Palatin Technologies (PTN – Research Report), with a price target of $2.75. The company’s shares closed on Friday at $1.42, close to its 52-week

Analysts Offer Insights on Healthcare Companies: Savara Inc (NASDAQ: SVRA), Puma Biotechnology (NASDAQ: PBYI) and Bluebird Bio (NASDAQ: BLUE)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Savara Inc (SVRA – Research Report), Puma Biotechnology (PBYI – Research Report) and Bluebird Bio (BLUE – Research Report). Savara Inc (SVRA) Ladenburg analyst Michael

Ladenburg Reaffirms Their Buy Rating on Acelrx (ACRX)

In a report released today, Michael Higgins from Ladenburg maintained a Buy rating on Acelrx (ACRX – Research Report), with a price target of $10. The company’s shares closed yesterday at $3.51. Higgins observed: “We are not at all dismayed

Analysts Offer Insights on Healthcare Companies: Paratek Pharmaceuticals (NASDAQ: PRTK) and Nektar Therapeutics (NASDAQ: NKTR)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Paratek Pharmaceuticals (PRTK – Research Report) and Nektar Therapeutics (NKTR – Research Report) with bullish sentiments. Paratek Pharmaceuticals (PRTK) Ladenburg analyst Michael

Ladenburg Believes Zynerba Pharmaceuticals (NASDAQ: ZYNE) Still Has Room to Grow

Ladenburg analyst Michael Higgins maintained a Buy rating on Zynerba Pharmaceuticals (ZYNE – Research Report) today and set a price target of $26. The company’s shares opened today at $11.80, close to its 52-week high of $13.06. Higgins noted: “We